Sequencing analysis of TP53 genes related to the LI-fraumeni syndrome study, in support of the NCI/dceg/ clinical genetics branch

Ended Awarded Last action

Contract number
HHSN26100001
Awardee
Awarding agency
Obligated
$1,313

Award facts

Opportunity
Contract value 100% obligated
$1,312.50 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Elmwood Park, NJ 07407, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00001 · DE-obligation of funds from FY2015 expiring lines. -$2,153
Original award $3,465

About this award

The National Cancer Institute issued a delivery order to Genedx, LLC on September 9, 2015, for sequencing analysis of TP53 genes related to the Li-Fraumeni Syndrome Study in support of the NCI/DCEG Clinical Genetics Branch, with a ceiling value of $1,312.50.

Place of performance is Elmwood Park, NJ. The order is firm fixed-price and has an ultimate completion date of September 8, 2016. No set-aside was used.

Quick answers

Who was awarded contract HHSN26100001?

HHSN26100001 was awarded to Genedx, LLC by National Cancer Institute (National Institutes of Health) on September 9, 2015.

How much is contract HHSN26100001 worth?

The government has obligated $1,313 on HHSN26100001.

Is contract HHSN26100001 an order under another contract?

Yes. HHSN26100001 is a delivery order under HHSN261201500016I, an indefinite delivery contract.

Was contract HHSN26100001 competed?

The extent of competition for HHSN26100001 was competed under sap.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award